Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05864144 · ClinicalTrials.gov registry record · Phase 1

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Sensei Biotherapeutics.

Active
Registry status
Phase 1
Development phase
98
Enrollment target
10
Study locations

NCT05864144 is a Phase 1 study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Sensei Biotherapeutics. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05864144, a Phase 1 study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Sensei Biotherapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
98 participants
Enrollment target
10
Study locations

Study Summary

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Conditions Studied

Breast Cancer Prostate Cancer Pancreatic Cancer Head and Neck Cancer Advanced Solid Tumor Gastric Cancer Esophageal Cancer Colon Cancer Solid Tumor, Adult Uterine Cancer

Interventions

  • DRUG Cemiplimab
  • DRUG SNS-101 (anti-VISTA)

Study Locations (10)

Texas

  • NEXT Oncology Dallas - Irving
  • South Texas Accelerated Research Therapeutics (START) San Antonio - San Antonio

California

  • UCLA Hematology/Oncology - Los Angeles

Colorado

  • University of Colorado Cancer Center - Anschutz Medical - Aurora

Kentucky

  • Norton Healthcare - Louisville

Michigan

  • Henry Ford Cancer - Detroit

New York

  • Icahn School of Medicine at Mt. Sinai - New York

Pennsylvania

  • University of Pennsylvania, Perelman Center for Advanced Medicine - Philadelphia

South Dakota

  • Sanford Cancer Center - Sioux Falls

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2023-05-31
Est. Completion 2027-06
Phase Phase 1

Sponsor

Sensei Biotherapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05864144

The ClinicalTrials.gov registry entry for NCT05864144 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Sensei Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT05864144 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05864144 about?

NCT05864144 is a clinical study titled "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors". Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

What is the current status of trial NCT05864144?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-05-31. Estimated completion is 2027-06.

What conditions does trial NCT05864144 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Pancreatic Cancer, Head and Neck Cancer, Advanced Solid Tumor.

What interventions are being tested in trial NCT05864144?

The interventions under investigation include: Cemiplimab (DRUG), SNS-101 (anti-VISTA) (DRUG).

Who is sponsoring clinical trial NCT05864144?

This trial is sponsored by Sensei Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05864144 being conducted?

This trial has 10 study locations across California, Colorado, Kentucky, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.